Deepwise Medical Secures Hundreds of Millions in Series C+ Funding, Steadily Entering a New Era of AI-Driven Healthcare

VCBeat (WeChat ID: vcbeat) has learned that DeepWise announced today the completion of its C+ round financing, amounting to hundreds of millions of yuan. This follows the company’s recent approval of a Class III medical device registration certificate from China’s National Medical Products Administration (NMPA) for its innovative AI product. The round was led by Zhongguancun Longmen Investment, with participation from Shanghai Lianxin Capital and other institutions. Existing investor Legend Capital continued to increase its investment in this round. With this achievement, DeepWise has completed five rounds of financing within four years, maintaining a leading position in the industry in terms of both fundraising speed and scale.

The lead investor in this round is Zhongguancun Longmen Investment, a market-oriented investment management firm jointly initiated by prominent entrepreneurs and seasoned investors, with the National Social Security Fund, the Beijing Municipal Government, and the Haidian District Government serving as cornerstone investors. Committed to facilitating the “critical leap” for exceptional enterprises, Longmen Investment strives to become the preferred collaboration platform for industry leaders. The co-investor, Lianyi Fund under Shanghai Lianxin Capital, is an investment platform jointly funded by Shanghai state-owned assets, including the Shanghai State-owned Assets Supervision and Administration Commission and Shanghai Pharmaceuticals Group. Adhering to the principle of “growing together with great enterprises,” it has nurtured a cohort of industry pioneers.

Regarding the investment in DeepWise, Fan Zhe, Partner at Longmen Investment, stated: “The development of artificial intelligence has been identified as a key focus area for strengthening China’s national strategic scientific and technological capabilities. With the recent rollout of review standards for Class III medical device certifications for AI healthcare products, the industry is entering a period of rapid growth, underscoring the strong support for innovation. In the field of AI-enabled smart healthcare, we have consistently focused on companies with genuine innovative capabilities.”“Although DeepWise is a young company, it has leveraged its robust R&D capabilities and its commitment to clinical exploration to build a comprehensive portfolio of AI-powered smart imaging products, thereby establishing a distinctive competitive moat from multiple perspectives. As an investor that supports innovative leading enterprises and serves as a key partner to industry leaders, Longmen Investment will continue to empower the company’s healthy growth across various dimensions.”

Li Jiaqing, Managing Director and Chief Investment Officer of Legend Capital, stated, “Legend Capital is optimistic about the application prospects of AI in medical services and drug R&D,”“DeepWise integrates information technology, medical diagnostic techniques, and engineering applications. It not only boasts industry-leading high-tech research achievements but also demonstrates strong productization capabilities, enabling rapid deployment in clinical scenarios. We remain bullish on DeepWise’s future development and continue to monitor investment opportunities in AI-driven vertical sectors, including healthcare.”

In China, medical artificial intelligence (AI) enjoys inherent advantages in its development. On one hand, the vast amount of medical data generated by China’s huge population provides a solid foundation for the advancement of medical AI. On the other hand, China’s expansive market offers sufficient impetus for innovation in this field. The medical AI industry has been developing vigorously, attracting significant capital interest, with frequent large-scale financing rounds particularly before 2018. As the industry rapidly progresses, recent years have seen a process of natural selection within the medical AI sector, with capital investment becoming more rational and placing greater emphasis on companies’ core competitiveness. Strong industry influence, robust R&D capabilities, broad application prospects, and clear strategic roadmaps best demonstrate such core competitiveness. DeepWise’s latest round of financing further validates current investment trends in the capital market.

Commenting on the successful completion of this funding round, Qiao Xin, Co-founder and CEO of DeepWise, stated:“The national strategic framework for innovation-driven development has created favorable opportunities for companies like DeepWise, which prioritize innovation as their primary growth engine. This year marks a pivotal phase for the clinical deployment of medical AI products, with a growing number of leading AI enterprises obtaining Class III medical device certifications. DeepWise has also been honored to gain approval through the NMPA’s Innovative Medical Device Special Examination Program. The regulatory clearance of medical AI solutions demonstrates the Chinese government’s increasing investment in encouraging R&D innovation in medical devices, promoting the application of new technologies, and fostering high-quality industry development. These efforts will contribute to the healthy advancement of the entire healthcare sector, spur the emergence of more high-tech enterprises like DeepWise, and pave the way for a promising future.”

“Only products that align with application scenarios and provide effective support across diagnosis, treatment, scientific research, and other levels can truly possess commercial value and enter the market. We are deeply grateful to DeepWise’s investors for their continued trust and support,” said Qiao Xin. “Since our first round of financing, when we outlined DeepWise’s strategic plan and vision to our investors, we have completed five funding rounds. I feel that we have been working alongside a group of like-minded friends to realize the blueprint in our hearts. While new partners have joined us, our original aspiration has never changed. Each financing round has perfectly aligned with DeepWise’s development strategy, and the latest infusion of capital will bring us one step closer to our ideal. With the introduction of various favorable national policies, the industry will experience healthy growth in a more standardized manner, and we will steadily enter a promising new era of medical AI.”

Founded in 2017, DeepWise has continuously redefined industry expectations for product development speed with its robust R&D capabilities. As a national high-tech enterprise, DeepWise operates independent subsidiaries in Beijing, Hangzhou, and Shanghai. The company brings together top-tier professionals from diverse fields, including artificial intelligence, internet cloud computing, and medical imaging. Its core department, the DeepWise Research Institute, boasts an unrivaled scale within the industry. Dedicated to exploring cutting-edge medical technologies, the institute is responsible for the algorithmic research and development of the company’s core products. It has produced numerous scientific achievements that combine clinical value with technological innovation, accumulating a total impact factor of nearly 170 for published academic papers and securing nearly 150 patents and software copyrights (either granted or under review). Currently, DeepWise undertakes multiple major special research projects funded by the Ministry of Science and Technology, the National Natural Science Foundation of China, and various major cities across the country. By engaging in in-depth collaborations with relevant national authorities, university research teams, and leading domestic medical institutions, DeepWise is fully committed to accelerating the translation of scientific achievements into clinical applications.

During the 2020 battle against the epidemic, DeepWise leveraged its substantial product expertise to respond rapidly, deploying its AI-assisted pneumonia diagnostic system to Hubei Province at the earliest opportunity. The company contributed to epidemic prevention and control through AI-assisted diagnosis, remote consultation platforms, AI-enabled remote diagnostic support, precision treatment, research-driven clinical support, and 5G+AI integration, earning repeated recognition and commendations from relevant authorities, including the National Health Commission, the Ministry of Industry and Information Technology, and People’s Daily Online.

Leveraging application scenarios in smart healthcare, DeepWise is building a robust artificial intelligence ecosystem. By continuously addressing clinical needs, the company is developing AI-powered intelligent imaging solutions that span from individual steps to the entire clinical diagnostic workflow; delivering closed-loop AI-driven smart services ranging from intelligent triage and appointment scheduling to follow-up management; establishing a multimodal AI platform for specific diseases that integrates high-dimensional data across medical imaging, text, laboratory tests, pathology, and genomics; and advancing multimodal smart research capabilities from basic statistics to machine learning and deep learning. Through the complementary advantages of its diversified product portfolio, DeepWise continues to explore and progress in the field of medical AI. The innovative strengths of AI will enhance patient care experiences, improve the efficiency and accuracy of physicians’ work, and support the intelligent management of hospitals, thereby effectively implementing the “Healthy China 2030” strategy and providing solid technical support for the intelligent transformation of the healthcare sector.